TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Workplace "Sit Less and Move More" Web-based Program (Walk@WorkSpain) on Occupational Sedentary Behavior, Habitual Physical Activity, Physical Risk Factors for Chronic Disease and Efficiency-related Outcomes in Spanish Office Employees
Brief Summary: This study assesses the short and mid-term impacts of a workplace web-based intervention (Walk@WorkSpain, W@WS) on self-reported occupational sitting time, step counts, activity-related energy expenditure, physical risk factors for chronic disease and efficiency-related outcomes in Spanish office employees. Half of participants had access to the W@WS website program while the other half was asked to maintain habitual behaviour.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: A workplace "sit less and move more" web-based program for Spanish office employees | Arm Label: Active comparison group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparison group | Intervention Type: BEHAVIORAL; Name: A workplace "sit less and move more" web-based program for Spanish office employees; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Active Comparison group; Assigned to Arm(s): Active comparison group
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Sit-stand workstation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Sit-stand workstation; Assigned to Arm(s): Intervention
C: Arm Label: Treadmill workstation; Type: EXPERIMENTAL; Interventions: Behavioral: Treadmill workstation, Behavioral: Health talk | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Behavioral: Health talk | Intervention Type: BEHAVIORAL; Name: Treadmill workstation; Assigned to Arm(s): Treadmill workstation | Intervention Type: BEHAVIORAL; Name: Health talk; Assigned to Arm(s): Control group, Treadmill workstation
D: Arm Label: Move; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Move | Arm Label: Stand & Move; Type: EXPERIMENTAL; Interventions: Device: Sit-Stand workstation, Behavioral: Move | Intervention Type: DEVICE; Name: Sit-Stand workstation; Assigned to Arm(s): Stand & Move | Intervention Type: BEHAVIORAL; Name: Move; Assigned to Arm(s): Move, Stand & Move

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Workplace "Sit Less and Move More" Web-based Program (Walk@WorkSpain) on Occupational Sedentary Behavior, Habitual Physical Activity, Physical Risk Factors for Chronic Disease and Efficiency-related Outcomes in Spanish Office Employees
Brief Summary: This study assesses the short and mid-term impacts of a workplace web-based intervention (Walk@WorkSpain, W@WS) on self-reported occupational sitting time, step counts, activity-related energy expenditure, physical risk factors for chronic disease and efficiency-related outcomes in Spanish office employees. Half of participants had access to the W@WS website program while the other half was asked to maintain habitual behaviour.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: A workplace "sit less and move more" web-based program for Spanish office employees | Arm Label: Active comparison group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparison group | Intervention Type: BEHAVIORAL; Name: A workplace "sit less and move more" web-based program for Spanish office employees; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Active Comparison group; Assigned to Arm(s): Active comparison group
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Sit-stand workstation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Sit-stand workstation; Assigned to Arm(s): Intervention
C: Arm Label: tailored group; Type: EXPERIMENTAL; Interventions: Behavioral: Start to stand | Arm Label: generic group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: generic advice | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Start to stand; Assigned to Arm(s): tailored group | Intervention Type: BEHAVIORAL; Name: generic advice; Assigned to Arm(s): generic group
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walkadoo | Intervention Type: BEHAVIORAL; Name: Walkadoo; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation: a Prospective Multicenter Registry-based Non-inferiority Randomized Controlled Clinical Trial
Brief Summary: This study will compare early with late start of treatment with Non-vitamin K oral anticoagulation (NOAC) in adult patients with acute ischemic stroke and atrial fibrillation; it is a registry-based randomized clinical trial (R-RCT) using The Swedish Stroke Register (Riksstroke). Half of the patients will start NOAC early (within 4 days after stroke onset) while the other half will start late (5-10 days after stroke onset).


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
B: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
C: Arm Label: Early start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Early start of NOAC | Arm Label: Late start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Late start of NOAC | Intervention Type: OTHER; Name: Early start of NOAC; Assigned to Arm(s): Early start of NOAC | Intervention Type: OTHER; Name: Late start of NOAC; Assigned to Arm(s): Late start of NOAC
D: Arm Label: Clopidogrel-aspirin; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel-aspirin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Clopidogrel-aspirin; Assigned to Arm(s): Clopidogrel-aspirin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation: a Prospective Multicenter Registry-based Non-inferiority Randomized Controlled Clinical Trial
Brief Summary: This study will compare early with late start of treatment with Non-vitamin K oral anticoagulation (NOAC) in adult patients with acute ischemic stroke and atrial fibrillation; it is a registry-based randomized clinical trial (R-RCT) using The Swedish Stroke Register (Riksstroke). Half of the patients will start NOAC early (within 4 days after stroke onset) while the other half will start late (5-10 days after stroke onset).


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Other: Rivaroxaban-Placebo | Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (Aspirin, BAY1019036), Other: Aspirin-Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Acetylsalicylic acid (Aspirin, BAY1019036); Assigned to Arm(s): Aspirin | Intervention Type: OTHER; Name: Rivaroxaban-Placebo; Assigned to Arm(s): Rivaroxaban | Intervention Type: OTHER; Name: Aspirin-Placebo; Assigned to Arm(s): Aspirin
C: Arm Label: Early start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Early start of NOAC | Arm Label: Late start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Late start of NOAC | Intervention Type: OTHER; Name: Early start of NOAC; Assigned to Arm(s): Early start of NOAC | Intervention Type: OTHER; Name: Late start of NOAC; Assigned to Arm(s): Late start of NOAC
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem®) in Patients With Ischemic Stroke
Brief Summary: The primary objectives of this study is to evaluate the efficacy of HLCM051 on functional outcome in subjects with acute ischemic stroke and to evaluate the safety of HLCM051 in subjects with acute ischemic stroke.


Options:
A: Arm Label: HLCM051 (MultiStem); Type: EXPERIMENTAL; Interventions: Biological: HLCM051 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: HLCM051; Assigned to Arm(s): HLCM051 (MultiStem) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Autologous bone marrow stem cell; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow stem cell | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow stem cell; Assigned to Arm(s): Autologous bone marrow stem cell
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: MultiStem, Biological: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: MultiStem, Biological: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: MultiStem, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MultiStem; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3
D: Arm Label: Stem Cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow mononuclear cell transplantation | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow mononuclear cell transplantation; Assigned to Arm(s): Stem Cells

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pathway Taking Into Account PeriConceptional Environment for Infertile Couple
Brief Summary: Infertility is defined as the inability to conceive after 12 months of unprotected intercourse, It affects approximately one in six couples pregnancy. Many lifestyle factors of the couple's pre and peri-conceptional environment (weight, diet, alcohol, tobacco, coffee, drugs, exercise, stress, sleep, pollution...) are risk factors for infertility. Weight gain, in both members of the couple, is associated with an increased risk of Assisted Reproduction Technology (ART) failure and adverse pregnancy outcome, while healthy lifestyle makes the risk of infertility three times less likely to happen. Idiopathic infertility may greatly benefit from lifestyle factors optimization.


Options:
A: Arm Label: Resveratrol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Resveratrol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo pills | Intervention Type: DIETARY_SUPPLEMENT; Name: Resveratrol; Assigned to Arm(s): Resveratrol | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo pills; Assigned to Arm(s): Control
B: Arm Label: Low Glycemic Index Diet Group; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index Diet Group | Arm Label: Conventional Diet Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Diet Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Glycemic Index Diet Group; Assigned to Arm(s): Low Glycemic Index Diet Group | Intervention Type: OTHER; Name: Conventional Diet Group; Assigned to Arm(s): Conventional Diet Group
C: Arm Label: PreLiFe-programme; Type: EXPERIMENTAL; Interventions: Behavioral: PreLiFe-programme, Behavioral: Attention Control Programme | Arm Label: Attention Control; Type: OTHER; Interventions: Behavioral: Attention Control Programme | Intervention Type: BEHAVIORAL; Name: PreLiFe-programme; Assigned to Arm(s): PreLiFe-programme | Intervention Type: BEHAVIORAL; Name: Attention Control Programme; Assigned to Arm(s): Attention Control, PreLiFe-programme
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PEPCI group; Type: EXPERIMENTAL; Interventions: Procedure: PEPCI | Intervention Type: PROCEDURE; Name: PEPCI; Assigned to Arm(s): PEPCI group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VENS is a Multicenter, Randomized, Double-masked, Placebo Parallel Controlled Trial to Evaluate the Efficacy and Safety of Treatment With Vitamin E Softgel in Non Diabetic Adults With NASH Compared to Treatment With Placebo in China
Brief Summary: VENS is a multicenter, randomized, double-masked, placebo parallel controlled trial to evaluate the efficacy and safety of treatment with vitamin E softgel in non diabetic adults with NASH compared to treatment with placebo in China.


Options:
A: Arm Label: caffeine and chlorogeinc acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: caffeine and chlorogenic acid | Arm Label: caffeine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: caffeine | Arm Label: chlorogenic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: chlorogenic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: caffeine and chlorogenic acid; Assigned to Arm(s): caffeine and chlorogeinc acid | Intervention Type: DIETARY_SUPPLEMENT; Name: caffeine; Assigned to Arm(s): caffeine | Intervention Type: DIETARY_SUPPLEMENT; Name: chlorogenic acid; Assigned to Arm(s): chlorogenic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Mastiha; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Mastiha | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Mastiha; Assigned to Arm(s): Mastiha | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Polyunsaturated fatty acid (Opti-EPA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyunsaturated fatty acid (Opti-EPA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Polyunsaturated fatty acid (Opti-EPA); Assigned to Arm(s): Polyunsaturated fatty acid (Opti-EPA) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: treatment group; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E softgel | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin E softgel; Assigned to Arm(s): treatment group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: In this study, the investigators varied the portion size of all meals served during two 5-day periods. During one period, baseline amounts of all foods and beverages were served, and during the other, the portion size of all items was increased by 50%. The primary aim of the study is to determine the effect of varying the portion size of foods and beverages served over 5 days on energy intake in preschool children.


Options:
A: Intervention Type: BEHAVIORAL; Name: Physical activity and diet; Assigned to Arm(s): N/A
B: Arm Label: I, Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: II, Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): I, Intervention
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Childhood Obesity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Childhood Obesity; Assigned to Arm(s): Treatment
D: Arm Label: 100% Portion Size; Type: EXPERIMENTAL; Interventions: Other: Food and Beverage Portion Size | Arm Label: 150% Portion Size; Type: EXPERIMENTAL; Interventions: Other: Food and Beverage Portion Size | Intervention Type: OTHER; Name: Food and Beverage Portion Size; Assigned to Arm(s): 100% Portion Size, 150% Portion Size

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: In this study, the investigators varied the portion size of all meals served during two 5-day periods. During one period, baseline amounts of all foods and beverages were served, and during the other, the portion size of all items was increased by 50%. The primary aim of the study is to determine the effect of varying the portion size of foods and beverages served over 5 days on energy intake in preschool children.


Options:
A: Arm Label: Individualized dietetic intervention; Type: OTHER; Interventions: Behavioral: Individualized dietetic intervention-eating habits | Intervention Type: BEHAVIORAL; Name: Individualized dietetic intervention-eating habits; Assigned to Arm(s): Individualized dietetic intervention
B: Arm Label: Home-based promotora intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based promotora family intervention | Arm Label: Delayed treatment control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home-based promotora family intervention; Assigned to Arm(s): Home-based promotora intervention
C: Arm Label: 100% Portion Size; Type: EXPERIMENTAL; Interventions: Other: Food and Beverage Portion Size | Arm Label: 150% Portion Size; Type: EXPERIMENTAL; Interventions: Other: Food and Beverage Portion Size | Intervention Type: OTHER; Name: Food and Beverage Portion Size; Assigned to Arm(s): 100% Portion Size, 150% Portion Size
D: Arm Label: Standard well child care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food Activity Breast feeding support; Type: EXPERIMENTAL; Interventions: Behavioral: FAB | Arm Label: Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: Sleep | Arm Label: FAB + Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: FAB, Behavioral: Sleep | Intervention Type: BEHAVIORAL; Name: FAB; Assigned to Arm(s): FAB + Sleep, Food Activity Breast feeding support | Intervention Type: BEHAVIORAL; Name: Sleep; Assigned to Arm(s): FAB + Sleep, Sleep

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blinded, Randomized Control Trial of Prophylactic Ondansetron in a Post-operative Cardiac Surgery Population for Post-operative Nausea and Vomiting
Brief Summary: To evaluate the effectiveness of a prophylactic dose of ondansetron in decreasing the incidence of post-operative nausea and vomiting in cardiac surgery patients after cessation of post-operative sedation. In patients who have undergone open heart surgery, a single prophylactic dose of ondansetron 4 mg IV given at the time of discontinuing propofol sedation will result in a 50% reduction of the rate of post-operative nausea and vomiting in the first 24 post-operative hours compared to placebo.


Options:
A: Arm Label: Gabapentin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin | Arm Label: ramosetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramosetron | Arm Label: Gabapentin and ramosetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin and Ramosetron | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin | Intervention Type: DRUG; Name: Ramosetron; Assigned to Arm(s): ramosetron | Intervention Type: DRUG; Name: Gabapentin and Ramosetron; Assigned to Arm(s): Gabapentin and ramosetron
B: Arm Label: Ondansetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ondansetron | Arm Label: Granisetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granisetron | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Granisetron
C: Arm Label: Ondansetron; Type: EXPERIMENTAL; Interventions: Drug: Ondansetron | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline
D: Arm Label: Ultrasound guided bilateral TAP block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transversus abdominis plane block (TAP BLOCK) | Arm Label: Instillation of surgical site with local anesthestic.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Instillation of surgical site with local anesthetic. | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Opioid IV medications (Control) | Intervention Type: PROCEDURE; Name: Transversus abdominis plane block (TAP BLOCK); Assigned to Arm(s): Ultrasound guided bilateral TAP block | Intervention Type: PROCEDURE; Name: Instillation of surgical site with local anesthetic.; Assigned to Arm(s): Instillation of surgical site with local anesthestic. | Intervention Type: PROCEDURE; Name: Opioid IV medications (Control); Assigned to Arm(s): Control Group

Answer: C